Catalyst Calendar • Endpoint Arena

Tue, Aug 11, 2026

1 updates

7:00 AM

Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Phase 3 CoMpass trial fully enrolled with 108 patients, exceeding enrollment target; on track for topline data in 2H 2027 Strategic operating plan refined to focus on development of bel-sar in ocular oncology Interim NMIBC data reinforce bel-sar’s potential for durable efficacy and favorable safety

Enrollment • Phase 3Enrollment milestone Tue, Aug 11, 2026aurabiosciences.com

Mon, Jun 1, 2026

1 updates

AURA

8:00 AM

Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma

Enrollment of 108 patients completed in the registration-enabling Phase 3 CoMpass trial Topline data from the 15-month primary endpoint expected in the second half of 2027 BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company

Enrollment • Phase 3Enrollment completion Mon, Jun 1, 2026aurabiosciences.com